Drug profile

The FDA adverse-event record for Rivaroxaban

10 FDA reports name Rivaroxaban, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2639 of 2,679
by report volume (all drugs)
10
adverse-event reports
10.0%
death-coded share
Cat
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Rivaroxaban ranks #2536 of 2679 by total reports (10). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2536
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Signature read: 10 reports place Rivaroxaban in the lower third of FDA AER volume (#2639 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
10
Total Reports
1
Deaths Reported
10.0%
Death-coded share of reports

Active Ingredients

Rivaroxaban

Administration Routes

UnknownOral

Species Affected

Cat 5
Dog 4
Human 1

Most Affected Breeds

Sphynx 2
Domestic Shorthair 2
Collie - Border 1
Unknown 1
Siberian 1
Retriever - Chesapeake Bay 1
Shepherd Dog - Australian 1
Chihuahua 1

Most Reported Reactions

Application site crust 2
Application site scab 2
Application site reaction NOS 2
Application site reddening 2
Blood clot 2
Gingival hyperplasia 1
Nervousness 1
Feeling anxious 1
Weight loss 1
Ocular discharge 1
Squinting 1
Renal disorder NOS 1

Outcome Breakdown

Outcome Unknown
6 (60.0%)
Ongoing
2 (20.0%)
Died
1 (10.0%)
Recovered/Normal
1 (10.0%)

Rivaroxaban: lower report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Rivaroxaban (#2639 of 2,679 by report volume); death-coded 10.0%. PlainBreed drug row · report volume stamp 10 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →